kloe THYE a
Hypersensitivity to cyclothiazide or any component; cross-sensitivity with
other thiazides or sulfonamides; anuria; renal
Use with caution in severe renal disease. Electrolyte disturbances
(hypokalemia, hypochloremic alkalosis, hyponatremia) can occur. Use with caution
in severe hepatic dysfunction; hepatic encephalopathy can be caused by
electrolyte disturbances. Gout can be precipitate in certain patients with a
history of gout, a familial predisposition to gout, or chronic renal failure.
Cautious use in diabetics; may see a change in glucose control. I.V. use is
generally not recommended (but is available). Hypersensitivity reactions can
occur. Can cause SLE exacerbation or activation. Use with caution in patients
with moderate or high cholesterol concentrations. Photosensitization may occur.
Correct hypokalemia before initiating therapy.
1% to 10%: Hypokalemia
<1% (Limited to important or life-threatening symptoms): Hypotension,
fluid and electrolyte imbalances (hypocalcemia, hypomagnesemia, hyponatremia),
hyperglycemia, rarely blood dyscrasias, prerenal azotemia, photosensitivity
Angiotensin-converting enzyme inhibitors: Increased hypotension if
aggressively diuresed with a thiazide diuretic.
Beta-blockers increase hyperglycemic effects in Type 2 diabetes mellitus.
Cyclosporine and thiazides can increase the risk of gout or renal toxicity;
avoid concurrent use.
Digoxin toxicity can be exacerbated if a thiazide induces hypokalemia or
Lithium toxicity can occur by reducing renal excretion of lithium; monitor
lithium concentration and adjust as needed.
Neuromuscular blocking agents can prolong blockade; monitor serum potassium
and neuromuscular status.
NSAIDs can decrease the efficacy of thiazides reducing the diuretic and
Adults: Oral: 2 mg/day; up to 2 mg 2-3 times/day
Serum electrolytes, renal function, blood pressure, I & O,
ammonia (B), amylase
(S), calcium (S), chloride
(S), cholesterol (S), glucose, uric acid (S);
(S), magnesium, potassium (S), sodium (S)
Thiazide diuretics are effective first-line therapeutic agents in the
management of hypertension and have proven to be of benefit in terms of
cardiovascular outcome. They may act synergistically to lower blood pressure
when combined with an ACE inhibitor or beta-blocker. The initial concern about
thiazide diuretic-induced hypokalemia, glucose intolerance, and lipid profiles
does not appear to be of substantial clinical consequence in the treatment of
hypertension. The benefits of this class of agents in the treatment of
hypertension is established and compares well with other first-line therapeutic
Tablet: 2 mg
"Consensus Recommendations for the Management of Chronic Heart Failure. On Behalf of the Membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure,"
Am J Cardiol, 1999, 83(2A):1A-38A.
Gibbons RJ, Chatterjee K, Daley J, et al,
"ACC/AHA/ACP-ASIM Guidelines for the Management of Patients With Chronic Stable Angina: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,"
J Am Coll Cardiol, 1999, 33(7):2092-197.
Ryan TJ, Anderson JL, Antman EM, et al,
"ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction),"
J Am Coll Cardiol, 1996, 28(5):1328-428.
"The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure,"
Arch Intern Med, 1997, 157(21):2413-46.
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved